MINIPRESS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MINIPRESS (MINIPRESS).

How it works

Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.

What the body does with it

Metabolism	Extensively metabolized in the liver via demethylation and conjugation, primarily by CYP3A4.
Excretion	Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Half-life	Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Protein binding	97-98% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Volume of Distribution	0.6-1.0 L/kg; reflects extensive distribution into extravascular tissues.
Bioavailability	Oral: 60-70% (extensive first-pass metabolism); bioavailability reduced with food.
Onset of Action	Oral: 1-2 hours (antihypertensive effect); peak plasma levels at 1-3 hours.
Duration of Action	Antihypertensive effect lasts 24 hours with once-daily dosing; orthostatic hypotension risk peaks 2-4 hours post-dose.

Classification & Brands

Dosing & administration

Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.

Dosage form	CAPSULE
Renal impairment	No specific dose adjustment required. Use with caution in severe renal impairment (CrCl < 10 mL/min) due to increased sensitivity.
Liver impairment	No specific dose adjustments for Child-Pugh A or B. For Child-Pugh C, consider dose reduction or increased dosing interval due to reduced clearance.
Pediatric use	Not approved for use in children. Safety and efficacy not established.
Geriatric use	Start at low end of dosing range (1 mg once or twice daily) due to increased risk of hypotension and falls. Titrate slowly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MINIPRESS (MINIPRESS).

Breastfeeding	Excreted in breast milk in small amounts (M/P ratio 0.5-1.0). Considered compatible with breastfeeding due to low infant dose; monitor infant for hypotension.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: animal studies show reduced fetal survival; human data limited, risk cannot be excluded. Second/third trimester: may cause hypotension in fetus/newborn; use only if benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to prazosin or any component of the formulation; concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil) may increase risk of hypotension."]

Clinical Precautions

Precautions

["Syncope and orthostatic hypotension, especially with first dose (first-dose effect); risk of priapism; caution in patients with renal impairment; use with caution in patients receiving beta-blockers or diuretics due to additive hypotensive effects."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MINIPRESS

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MINIPRESS (MINIPRESS).

How it works

Selective antagonist of postsynaptic alpha-1 adrenergic receptors, inhibiting vasoconstriction and reducing peripheral vascular resistance.

What the body does with it

Metabolism	Extensively metabolized in the liver via demethylation and conjugation, primarily by CYP3A4.
Excretion	Primarily hepatic metabolism (90%) with <10% excreted unchanged in urine; 50-60% of metabolites eliminated in bile/feces, 40-50% in urine.
Half-life	Terminal elimination half-life is 2-3 hours; clinical effect persists longer (up to 24 hours) due to sustained receptor binding.
Protein binding	97-98% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Volume of Distribution	0.6-1.0 L/kg; reflects extensive distribution into extravascular tissues.
Bioavailability	Oral: 60-70% (extensive first-pass metabolism); bioavailability reduced with food.
Onset of Action	Oral: 1-2 hours (antihypertensive effect); peak plasma levels at 1-3 hours.
Duration of Action	Antihypertensive effect lasts 24 hours with once-daily dosing; orthostatic hypotension risk peaks 2-4 hours post-dose.

Classification & Brands

Dosing & administration

Initial: 1 mg orally 2-3 times daily. Maintenance: 2-5 mg orally 2-3 times daily. Maximum: 20 mg/day.

Dosage form	CAPSULE
Renal impairment	No specific dose adjustment required. Use with caution in severe renal impairment (CrCl < 10 mL/min) due to increased sensitivity.
Liver impairment	No specific dose adjustments for Child-Pugh A or B. For Child-Pugh C, consider dose reduction or increased dosing interval due to reduced clearance.
Pediatric use	Not approved for use in children. Safety and efficacy not established.
Geriatric use	Start at low end of dosing range (1 mg once or twice daily) due to increased risk of hypotension and falls. Titrate slowly.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MINIPRESS (MINIPRESS).

Breastfeeding	Excreted in breast milk in small amounts (M/P ratio 0.5-1.0). Considered compatible with breastfeeding due to low infant dose; monitor infant for hypotension.
Teratogenic Risk	FDA Pregnancy Category C. First trimester: animal studies show reduced fetal survival; human data limited, risk cannot be excluded. Second/third trimester: may cause hypotension in fetus/newborn; use only if benefit outweighs risk.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

None.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to prazosin or any component of the formulation; concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil) may increase risk of hypotension."]